Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

11,118 total articles

Sandisk: AI-Driven NAND Shortage Could Keep the Rally Going

Sandisk: AI-Driven NAND Shortage Could Keep the Rally Going

Sandisk has re-rated sharply in 2026 on exploding AI demand for NAND flash. The shares trade at elevated multiples today, but fundamentals - double-digit returns on capital, robust free cash flow of $4.46B and locked-in supply deals - plus technical momentum and low days-to-cover make a controlled long entry attractive. We lay out a long trade for …

Buy FNF on Cheap Cash Flow and a Safe Yield - Tactical Swing Trade

Buy FNF on Cheap Cash Flow and a Safe Yield - Tactical Swing Trade

Fidelity National Financial (FNF) looks attractively priced after a pullback. Strong free cash flow, a sustainable quarterly dividend of $0.52, and reasonable leverage give shareholders both income and upside optionality. This trade targets a rebound toward the mid-$50s over a 45-trading-day horizon while limiting downside with a tight stop.

HF Sinclair: Ride the Refining Supercycle — Upgrade to Long Trade

HF Sinclair: Ride the Refining Supercycle — Upgrade to Long Trade

HF Sinclair (DINO) is an attractive long after recent weakness. The company sits squarely in the refining sweet spot created by Iran-related supply disruptions: elevated gasoline and diesel margins, strong free cash flow, and a conservative balance sheet. At current levels the stock offers upside to $80 while still protecting capital with a $54 sto…

Astera Labs: Betting on the Data-Movement Layer of the AI Build-Out

Astera Labs: Betting on the Data-Movement Layer of the AI Build-Out

Astera Labs builds high-speed connectivity silicon for rack-scale AI systems. With Q1 2026 revenue of $308.4M (+93% YoY), a Nasdaq-100 addition, and strong free cash flow, the company is priced for a dominant market narrative. This trade idea lays out an actionable long with entry, stop, and target plus the catalysts and risks that matter.

Why HPE Is the Pure-Play on Enterprise AI Infrastructure — A Buy Setup

Why HPE Is the Pure-Play on Enterprise AI Infrastructure — A Buy Setup

HPE sits squarely at the intersection of servers, storage, and networking for enterprise AI. Recent wins, a multi-billion dollar AI backlog and improving margins make it a high-conviction long. This trade lays out an entry, stop and target for a 180-trading-day horizon while flagging the operational and cyclical risks that could derail execution.

Buy the Dip: NVDA Is Cheap Relative to Its AI Franchise

Buy the Dip: NVDA Is Cheap Relative to Its AI Franchise

Nvidia ($205.65) is trading at a multi-year pullback amid profit-taking into new IPOs and sector rotation. Fundamentals remain robust - market cap roughly $5.03T, ROE ~81.7%, and free cash flow of $119B - and recent technicals offer a clean risk-reward for a long trade. This idea lays out an entry at $205.65, a stop at $192.00 and a primary target …

Buy Dynatrace on the AI-Observability Pullback - Target $50

Buy Dynatrace on the AI-Observability Pullback - Target $50

Dynatrace (DT) has been punished for decelerating ARR guidance and competitive headlines, but the company sits on healthy free cash flow, low leverage and a product well-aligned with rising AI agent complexity. This trade idea buys the dip with a mid-term horizon: entry $41.28, stop $38.00, target $50.00.

uniQure Re-Rates After FDA Tone Shift on AMT-130 - Momentum Trade Plan

uniQure Re-Rates After FDA Tone Shift on AMT-130 - Momentum Trade Plan

uniQure (QURE) ripped higher to $48.20 on 06/17/2026 after the market interpreted a recent FDA communication as more constructive for the AMT-130 Huntington's BLA pathway. Heavy volume, elevated short interest and a stretched technical picture create a trade that aims to capture momentum while respecting the very real regulatory and legal clearance…

Pfizer: Why I Still Expect a Big Rebound — a Concrete Trade Plan

Pfizer: Why I Still Expect a Big Rebound — a Concrete Trade Plan

Pfizer shares trade at ~$25.91 with a $147.5B market cap, a 6.6% dividend yield and an EV/EBITDA of 8.9. With positive GLP-1 data for berobenatide, solid free cash flow of ~$9.5B and a still-reasonable leverage profile, I see a clear path for a rebound into the low $30s over the next 180 trading days. This is an actionable long trade with defined e…